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Relation between tetR and tetA expression
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Abstract
Background: Tetracyclines are among the most used antibiotics in livestock worldwide. Resistance is widely
disseminated in Escherichia coli, where it is generally mediated by tetracycline efflux pumps, such as TetA.
Expression of tetracycline efflux pumps is tightly controlled by the repressor TetR, which has been shown to be
tetracycline-responsive at sub-MIC tetracycline concentrations. The objective of this study was to investigate the
effects of increasing tetracycline concentrations on the growth of TetA-producing E. coli, and to determine how
expression of tetA and tetR related to each other in different growth phases in the presence of tetracycline.
Results: A tetracycline resistant E. coli strain containing tetA and tetR on the chromosome was constructed and
cultured in the presence of increasing concentrations of tetracycline. Expression of tetR and tetA was measured
at four time points in different growth phases by quantitative real-time PCR. The TetA-producing E. coli exhibited
prolonged lag phase with increasing concentrations of tetracycline, while expression of tetA and tetR increased
and decreased, respectively, with increasing tetracycline concentration. The levels of tetA and tetR mRNA varied
depending on growth phase, resulting in a gradual decrease of the tetA/tetR ratio from approximately 4 in the
lag phase to approximately 2 in the stationary phase.
Conclusion: This study shows that the expression of tetR and tetA is tetracycline concentration- and growth
phase-dependent, contributing to improved understanding of the relationships between E. coli growth,
tetracycline exposure and expression of tetracycline resistance.
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Background
Tetracyclines exert their bacteriostatic activity by binding
to the bacterial ribosome and thereby interfering with pro-
tein translation [1]. Over the years, the prevalence of tetra-
cycline resistance has increased in bacteria isolated from
both human patients [2, 3] and animals [4]. In a study per-
formed by Tadesse et al. it was shown that the prevalence
of tetracycline resistance in Escherichia coli isolates from
humans increased by 0.45 % per year from 1950 to 2001
[5]. As a consequence of the spread of tetracycline resist-
ance and the introduction of newer and more effective
antimicrobial agents, the use of tetracylines in human
medicine has gradually decreased. However, tetracyclines
remain among the most used antibiotics in livestock
production worldwide [6]. In the European Union, they
account for 37 % of the total sales of antimicrobial agents
for livestock [7] and a significant association has been
observed at the country level between tetracycline con-
sumption and occurrence of tetracycline resistance among
E. coli isolated from livestock [8].
More than 40 genes encoding tetracycline resistance
(tet-genes) have been characterized to date and they are
divided into 11 classes, with a majority of classes (60 %)
encoding for membrane-associated efflux proteins [9–11].
These efflux pumps selectively transport tetracycline from
the cytosol to the periplasm in exchange of a proton,
thereby limiting the access of tetracycline to the ribosomes
in the cell [12]. They are proton motive force-dependent,
single polypeptide, drug specific efflux pumps, which be-
long to the major facilitator superfamily [12, 13]. The flow
of protons through the pump provides the required energy
to pump the antibiotic to the periplasm [9, 14]. In E. coli,
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tet-resistance efflux pumps are among the best character-
ized transport systems [12]. Studies from selected parts of
the United States of America list TetA as the second most
frequent tetracycline resistance efflux pump in both hu-
man and animal isolates [15]. TetA is also the most com-
mon tetracycline efflux pump type found in clinical as
well as commensal isolates of E. coli in animals from
Denmark [4].
Expression of TetA efflux pump is controlled through
a tetracycline-responsive repressor, TetR, which tightly
regulates the tetA mRNA expression [16, 17]. Studies
performed in the 1960-80s with sub-inhibitory (i.e.
below the minimum inhibitory concentration, MIC)
concentrations of tetracycline and derivatives thereof
[18–23] led to a widely accepted model for tetR and tetra-
cycline efflux pump gene regulation proposed by Hillen
and Berens [24]. According to this model, tetracycline in-
duces transcription of both the tetR and the tetracycline
efflux pump gene by binding to TetR (Fig. 1) [24–26].
Repression by TetR must be tight, because constitutive ex-
pression of the efflux pump strongly reduces bacterial fit-
ness [27]. It has never been determined how tetR and the
tetracycline efflux pump gene expression varies over a
range of tetracycline concentrations, and whether the
model description of regulation at low tetracycline con-
centrations fits tetracycline resistant E. coli that are faced
with fighting therapeutic concentrations of the antibiotic.
The aim of the current study was to investigate the growth
response of TetA-producing E. coli over a wide range of
tetracycline concentrations and to determine how tetA
and tetR expression were influenced by tetracycline con-
centrations and growth phase.
Fig. 1 TetR-tetA regulation model. Genetic organisation and mechanism of regulation of the Tn10-encoded tetracycline resistance determinant as
proposed by Hillen and Berens [24]. The upper part of the figure describes processes occurring at the cytoplasmic membrane, while the lower
part shows a schematic drawing of the genetic organisation and induction of the tetR and tetA genes. Tetracycline (tc) is assumed to enter the
outer membrane by porins [1, 46]. The [tc · Mg]+ complex is formed, however it can dissociate and tetracycline can enter the cell by diffusion
across the cytoplasmic membrane in its neutral form (middle). In the cytoplasm the [tc · Mg]+ complex is formed again. The same complex,
indicated by triangles, is the molecular inducer of the Tet repressor (circles), encoded by tetR (thick grey arrow, bottom). TetR forms a dimer and
binds to the two tandem tet operators O1 and O2 located between tetA and tetR in the absence of tetracycline. The genes have divergent
polarities and are transcribed from overlapping promoters. When tetracycline is present, the [tc · Mg]+ complex binds to the TetR repressor-
operator complex and triggers a conformational change in TetR so that it can no longer bind to the tet-operators, enforcing rapid dissociation
from the DNA, enabling transcription of tetR and tetA (bottom, center). The [tc · Mg]+ complex is the substrate of the proton-tetracycline antiporter
(TetA pump) which is indicated by its 12-α-helix membrane spanning structure. Modified from [9, 24]
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Methods
Bacterial strain construction
Bacteria and plasmids used in this study are listed in
Table 1. The tetA gene and its repressor tetR isolated from
an IncN plasmid obtained from E. coli of sow origin [28]
were cloned into the pseudo gene ybeM [29] on the
chromosome of E. coli K-12 MG1655, resulting in strain
MG1655/TetA. The tetA and tetR genes were cloned into
the chromosome of a laboratory E. coli strain to avoid
problems related to the plasmid (e.g. other resistance
genes encoded on the plasmid) and gene copy number.
The Lambda Red recombination system was used to con-
struct the strain, as described previously [30–32]. Se-
quences of oligonucleotides used for PCR verifications
and Lambda Red mediated mutagenesis are listed in
Table 2. Insertions were confirmed by PCR and sequen-
cing using standard procedures. The strain was main-
tained in Difco™ Lysogeny broth (LB), Lennox (Becton,
Dickinson and Company, Albertslund, Denmark) and on
LB agar plates (Becton, Dickinson and Company, Albert-
slund, Denmark). The media were supplemented with
tetracycline (10 μg/mL) (Sigma, Copenhagen, Denmark)
when appropriate.
Antimicrobial susceptibility testing
The broth microdilution method was used to deter-
mine the MIC of tetracycline following the CLSI
guidelines [33]. The tetracycline concentrations tested
ranged from 0 to 1024 μg/mL by two-fold dilution in-
crease. In addition, MIC determination was performed
using serial increases of 2 μg/mL of tetracycline in the
range close to the observed MIC to obtain a value as
close to the real MIC as possible. Furthermore, MIC
experiments with spent media containing tetracycline
(MG1655/TetA incubated in MH-2 with 8 μg/mL
tetracycline for 15 hours at 37 °C, centrifuged and fil-
ter sterilised) and media with tetracycline (MH-2 with
8 μg/mL tetracycline incubated for 15 hours at 37 °C)
were performed using the same method to test for
drug degradation and destruction.
Growth conditions
A BioScreen CTM was used to perform growth experi-
ments for 24 hours at 37 °C in biological triplicates. A
volume of 200 μL Müller-Hinton-II (MH-2) broth (Sigma,
Copenhagen, Denmark) was inoculated with cells from
blood agar plates (blood agar base (Oxoid, Roskilde,
Denmark) supplemented with 5 % blood from cattle) to a
final cell density of 106 cfu/mL, using a Sensititre™ Neph-
elometer (Thermo Scientific™, Roskilde, Denmark) with a
McFarland 0.5 standard (1–2 x 108 cfu/mL). The cultures
were supplemented with tetracycline (ranging from 0 to
128 μg/mL by two-fold dilutions). Optical density (OD, re-
corded with 600 nm filter) was measured every 5 minutes
keeping bacterial cultures under continuous shaking. The
specific maximum growth rate at different tetracycline
concentrations was calculated. For expression studies, the
strain was grown in 100 mL of MH-2 broth in 250 mL
flasks at 37 °C and 225 rpm. The medium was supple-
mented with three different concentrations of tetracycline
representing 1/8 MIC (3.5 μg/mL), ¼ MIC (7 μg/mL) and
½ MIC (14 μg/mL) of the strain and inoculated with a pre-
culture grown for 2 hours at 37 °C and 225 rpm using the
method described above. The tetracycline concentrations
represent therapeutic concentrations, according to pub-
lished pharmacokinetics data [34]. Although it has been
shown that tetracycline in water solution is stable for
3 days at 37 °C [35], and approximately 5 % tetracycline is
degraded after 2 days at 40 °C [36], we ensured that the
late growth onset in our growth studies was not due to
degradation of tetracycline by using an E. coli reference
strain (ATCC 25922) with a MIC of tetracycline of 2 μg/
mL [37]. E. coli ATCC 25922 was grown with the same
tetracycline concentrations as used for the tetracycline
resistant strain and MIC values were determined using
spent media.
RNA extraction
Samples for RNA extraction were collected at four differ-
ent time points during in vitro growth; the lag phase
(OD600nm = 0.1-0.2), the logarithmic phase (OD600nm =
0.5-0.6), the late logarithmic phase (OD600nm = 1-1.3) and
the stationary phase (OD600nm = 3.3-4.6). Sampling, RNA
extraction, DNase treatment and reverse transcription
were performed as previously described [38].
Quantitative real time polymerase chain reaction
Quantitative real time polymerase chain reaction (qPCR)
was performed using a LightCycler 96 (Roche, Hvidovre,
Denmark) as described previously [38]. Primers are listed
in Table 2. The genes gapA and nusG were used as refer-
ence genes according to previous validation experiments
[38]. Relative gene expression (fold change) was calculated
compared to the lag phase sample of strain MG1655/TetA
without antibiotics. Two independent biological replicates
Table 1 Bacterial strains and plasmids used in this study
Strain or plasmid Genotype Reference
or source
E. coli K-12
MG1655
Wild type [47]
MG1655/TetA E. coli MG1655 ΔYbeM::TetA (tetr) This work
IncN/TetA tetR and tetA containing plasmid [28]
pKD46-gm Vector for Lambda Red mediated
mutagenesis: λ-red expression from
arabinose-inducible promoter;
temperature sensitive (gmr)
[30]
E. coli ATCC 25922 Reference strain [48]
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were performed using two technical replicates and the 2-
ΔΔCt method, corrected by different primer efficiencies
and multiple reference genes was used [39].
Statistical analysis
Statistical analysis was performed as previously described
[38]. Briefly, the differences in the normalised qPCR mea-
surements between the tetracycline concentrations within
each growth phase were compared by differences in least
square means using analysis of variance. The Mixed
procedure in SAS version 9.3 (SAS Institute, Cary,
USA) was used and differences in least square means
estimates were evaluated with an approximate t-test
using the LSmeans-function. Differences between tetra-
cycline concentrations and growth phases were evaluated
by F-tests, and a P value < 0.05 was deemed statistically
significant. To correct for multiple comparisons of the
differences in the least-squares means, the Benjamini–
Hockberg ‘false discovery rate’ (FDR) was used [40].
Results and Discussion
Lag phase duration increases in the presence of
tetracycline in a concentration-dependent manner
The MIC of tetracycline for MG1655/TetA was 28 ±
2 μg/mL. Using a definition of lag phase as the time ne-
cessary to reach an OD600nm of 0.1, the lag phase length
increased when the tetracycline concentration was
above 2 μg/mL (Figure 2 and Additional file 1: Table S1).
The lag phase length increased from 4.28 ± 0.10 hours at
4 μg/mL tetracycline to 18.17 ± 3.67 hours at 16 μg/mL
tetracycline. In accordance with the MIC value, MG1655/
TetA did not grow at tetracycline concentrations above
16 μg/mL (Fig. 2). The ATCC 25922 reference strain did
not display growth at tetracycline concentrations other
than 0 μg/mL and 0.5 μg/mL (data not shown). With
0.5 μg/mL of tetracycline, the control strain started to
grow after 19 hours. No growth was observed above the
MIC of the reference strain (2 μg/mL) [37]. Furthermore,
MIC experiments with spent media containing tetracyc-
line and media incubated with tetracycline were per-
formed, and the reference strain showed the same MIC
towards tetracycline as using fresh tetracycline. These ex-
periments show that the tetracycline did not degrade dur-
ing the growth experiment, and that the prolonged lag
phase observed in the experiment was not attributable to
Table 2 Oligonucletide sequences for PCR based amplification and sequencing
Primer Sequence Application
TetA-ybeM for: 5’-ATGCTGGTGGCACTTCAGGCAGGAAACATCGTCGCCCGTTCAATCGTCACCCTTTCTCGG -3’ Recombination
rev: 5’-AGGCGGCAGGAAGTACCAGGATTTCAGCTCCCTGTCTATGTGCAACGGGAATTTGAAG-3’
TetA/ybeM for: 5’-GAAGCATTGCTGGCGCGCGATG-3’ Proof of insertion
rev: 5’-TTCTCCAAAGCCCGCGACGCAG-
TetA for: 5’-AAGAATCCGCGCGTTCAATCG-3’ Sequencing
rev: 5’-GCCCGGCACCGGCATAAT-3’
TetR for: 5’-TCGGATCCTCAATCGTCACCCTTT-3’ Sequencing
for: 5’-CGCATCCATGCCGGCACG-3’
NusG for: 5’-GTCCGTTCGCAGACTTTAAC-3’ qPCR
rev: 5’-GCTTTCTCAACCTGACTGAAG-3’
GapA for: 5’-ACTGACTGGTATGGCGTTCC-3’ qPCR
rev: 5’-GTTGCAGCTTTTTCCAGACG-3’
TetA-qPCR for: 5’-CGGTCTTCTTCATCATGCAAC -3’ qPCR
rev: 5’-GTCCCAGTGAAAGCGATCC-3’
TetR-qPCR for: 5’-CCGAATGCGTATGATTCTCC-3’ qPCR
rev: 5’-CGCTTTACTGGCACTTCAGC-3’
Fig. 2 Growth curves of the TetA-producing E. coli strain at different
concentrations of tetracycline. E. coli MG1655 containing tetR and
tetA on the chromosome (MG1655/TetA). The strain was grown in
MH-2 broth with different concentrations of tetracycline (TET) on a
BioScreen CTM. No growth was observed for the three highest
concentrations tested. Three independent replicates were performed;
the data shown represents the mean and dots represent
standard deviations
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drug degradation. A possible explanation to the long lag
phases observed in the presence of tetracycline is that the
levels of tetracycline need to be below a certain threshold
in the cytosol before growth can initiate. Based on the re-
sults of this experiment, the time to reach this threshold
level appears to be tetracycline concentration-dependent.
It is speculated that tetracycline concentrations up to a
certain level could be dealt with by increasing the num-
bers of TetA pumps in the membrane as the lag phase
was unchanged. Then a maximum level of pumps was
reached, and the lag phase increased as there presumably
were too few TetA pumps to deal with the high tetracyc-
line concentration.
The maximum specific growth rate of the strain
decreased with increasing tetracycline concentrations
(Additional file 1: Table S1), showing that increased
tetracycline concentrations resulted in slower growth.
However, this could not account for the increased lag
phase. Since the concentrations we have investigated
are within the range of those achieved during therapy
[34], these observations indicate that even in tetracycline-
resistant strains growth is delayed during therapy. A
recent model study of growth kinetics of tetracycline-
resistant strains during therapy in the gut of post
weaning pigs showed that resistant strains having a
10 % reduction in the growth rate still could colonize
and remain in the gut in a stable manner despite this
disadvantage [41].
Expression of tetR mRNA is tetracycline concentration-
and growth phase-dependent
The mRNA levels of tetR were significantly higher in
samples with the presence of tetracycline compared to
the absence of tetracycline (Fig. 3). A significant 3 to 25
fold increase was observed in the mRNA when the strain
was exposed to 3.5 μg/mL of tetracycline in the different
growth phases (adjusted P-values: 0.019 in lag phase,
0.002 in log phase, 0.005 in late log phase and 0.001 in
stationary phase). Significantly lower tetR mRNA levels
occurred when the strain was exposed to 7 μg/mL or
14 μg/mL of tetracycline, even though they were signifi-
cantly higher than the levels observed in absence of
tetracycline (Fig. 3). The decrease in expression with in-
creasing tetracycline concentrations was observed in all
growth phases, except in the lag phase. The decrease in
the mRNA level was significant between the samples
with 3.5 and 14 μg/mL tetracycline in the logarithmic
and late logarithmic phase (adjusted P-values: 0.023
and 0.029, respectively). All statistically significant P-values
of the observed differences are listed in Additional file 1:
Table S2. Overall, expression of tetR was shown to be tetra-
cycline concentration-dependent. The observed fluctua-
tions of tetR mRNA levels in cells exposed to different
concentrations of tetracycline represent valuable knowledge
when considering new treatment strategies for tetracycline
resistant E. coli strains. When treating infections with
tetracycline-resistant bacteria, it may not always be opti-
mal to increase the tetracycline concentration as the tetR
mRNA level will decrease, and thereby affect the tetA
mRNA level (see below).
Expression of tetR at a specific tetracycline concentra-
tion varied depending on growth phase (Fig. 3). The
level of tetR mRNA in MG1655/TetA increased from lag
to stationary phase at all concentrations tested. Statisti-
cally significant increases in the tetR mRNA level were
observed from logarithmic to stationary phase when the
strain was exposed to 7 μg/mL or 14 μg/mL of tetracyc-
line (adjusted P-values: 0.026 and 0.025, respectively, see
Additional file 1: Table S2).
Expression of tetA mRNA is also tetracycline- and growth
phase-dependent
Expression of tetA increased significantly when tetracyc-
line was present (Fig. 4), which is in accordance with the
previously described tetR-tetA regulation model [24].
Significant tetA mRNA level increments were observed
in the presence of tetracycline regardless of growth
phase (Additional file 1: Table S3). The tetA mRNA level
showed a tendency to increase with increasing concentra-
tions of tetracycline in the lag, logarithmic and late loga-
rithmic growth phases. Significant P-values for tetracycline
concentration-dependency are listed in Additional file 1:
Table S3. These results confirm that tetA expression is
Fig. 3 Relative changes in tetR mRNA levels. tetR mRNA profile of
E. coli MG1655 containing tetA and tetR on the chromosome
(MG1655/TetA). Growth was performed in MH-2 broth without and
with tetracycline at different concentrations. Two independent
replicates including two technical replicates each were performed;
the data shown represents the mean. The data have been normalised
to two validated reference genes, gapA and nusG, and are relative
to the tetR mRNA level in the lag phase with no antibiotics. The
error bars represent standard deviations
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dependent on the presence of tetracycline and influenced
by the drug concentration. Despite several attempts by us
to determine the TetA protein levels in the strain by
selected-reaction-monitoring mass spectrometry (SRM-
MS), it failed because the TetA protein could not be specif-
ically detected (methods and data not shown). Similarly,
western blot experiments could not be performed as TetA
could not be overproduced in order to get enough purified
protein to produce specific antibodies. When TetA over-
production was attempted by induction of a His-tagged or
glutathione S-transferase-tagged tetA with IPTG, to facili-
tate purification, bacterial cell viability was lost (data not
shown), which is in accordance with previous observations
by Eckert et al.247 Therefore it is currently unknown
whether high tetA mRNA levels lead to proportionally high
levels of TetA pumps. Assuming a positive correlation, the
results indicate that exposing tetracycline resistant E. coli
to high tetracycline concentrations will result in an in-
creased tetA mRNA level and therefore a higher number
of TetA pumps.
The tetA mRNA levels also varied according to growth
phase with different patterns depending on the presence
of tetracycline (Fig. 4). A decrease in tetA mRNA was ob-
served from lag to stationary phase in the absence of tetracyc-
line. In the presence of fixed concentrations of tetracycline,
the level of tetA mRNA increased from lag to logarithmic
phase (except in the logarithmic phase at 3.5 μg/mL tetracyc-
line) and stabilised in the late logarithmic phase. In the
stationary phase, the tetA mRNA level was approximately
twice of that observed in the late logarithmic growth
phase regardless of the drug concentration to which the
strain was exposed. Significant P-values for growth phase
dependency can be found in Additional file 1: Table S3.
tetA/tetR mRNA ratio
To observe more clearly how the mRNA level of tetA
related to tetR expression, the tetA/tetR ratio was calcu-
lated (Fig. 5). In all growth phases except the lag phase,
the tetA/tetR mRNA ratio was low in absence of tetra-
cycline, indicating low mRNA level of tetA compared to
tetR. This corroborates the model assumption that TetR
needs to be produced to block the expression of tetA.
When the strain was exposed to any of the tetracycline
concentrations used, which are above previously tested
concentrations, the tetA/tetR ratio increased markedly,
showing that much more tetA mRNA was present com-
pared to tetR mRNA, and this was especially observed in
the lag phase, where the tetA/tetR ratio was in the range
of 3.5-4.5 fold. Furthermore, the tetA/tetR ratio was
tetracycline concentration-dependent with higher tetA/
tetR mRNA ratios at higher drug concentrations in all
growth phases.
It is known that the TetR repressor protein has a 2-fold
higher affinity for the tetA proximal operator O2 site com-
pared to the tetR proximal operator O1 site [42]. This can
explain why much lower tetA/tetR mRNA ratios were ob-
served in the absence of tetracycline induction. In the
model, tetracycline binds to Mg2+, and these complexes
bind to TetR dimers and cause a conformational change
that makes the TetR protein unable to bind to the oper-
ator sites O1 and O2. This turns on the expression of both
tetA and tetR in a tetracycline-dependent manner. In a
Fig. 4 Relative changes in tetA mRNA levels. tetA mRNA profile of
E. coli MG1655 containing tetA and tetR on the chromosome
(MG1655/TetA). The strain was grown in MH-2 broth without and
with tetracycline at different concentrations. Two independent
replicates including two technical replicates each were performed;
the data shown represents the mean. The data have been normalised
to two validated reference genes, gapA and nusG, and are relative
to the tetA mRNA level in the lag phase with no antibiotics. The
error bars represent standard deviations
Fig. 5 tetA/tetR mRNA ratio. tetA/tetR mRNA ratios were calculated for
each biological replicate. The error bars represent standard deviations
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previous study the tetA promoter was found to be about
four times as strong as the two overlapping tetR pro-
moters together [43]. Another study performed by Daniels
et al. showed that the tetA promoter was 7–11 fold more
active than the tetR promoters combined [44]. A stronger
tetA promoter corresponds well with the rise in tetA/tetR
mRNA ratios in our studies with increasing concentra-
tions of tetracycline in the lag phase.
A tetracycline concentration-dependent change in
tetA/tetR mRNA ratio was found between growth phases
with a decrease from onset of growth to maximum
growth rate. We speculate that once growth is in the ex-
ponential phase, each cell contains the maximum level
of TetA pumps in the membrane. This facilitates that
enough tetracycline is pumped out to reach a critical
concentration below which TetR is again free to bind the
operator sites. TetR preferably binds to O2, which results
in blocking the transcription of tetA but not of tetR [45].
This explain the increase in tetR mRNA from lag to
logarithmic phase, the constant tetA mRNA level in lag,
logarithmic and late logarithmic phase (Figs. 3 and 4, re-
spectively), and the lowered tetA/tetR mRNA ratios in
the logarithmic, late logarithmic and stationary growth
phases compared to the lag phase (Fig. 5). The highest
tetA and tetR mRNA levels were observed at stationary
phase in the presence of tetracycline. However, interpret-
ation of transcriptional regulation from stationary
growth phase cultures should be done with caution due
to the cell complexity with a mixture of cells in different
physiological phases.
Conclusions
This study shows that a tetracycline resistant TetA-
producing E. coli exhibited prolonged lag phase with in-
creasing concentrations of tetracycline. This suggests that
even tetracycline-resistant strains are growth-detained in
the presence of tetracycline, likely due to the time needed
to express the resistance genes and export tetracycline out
of the cell. The expression of tetA and tetR increased and
decreased, respectively, with increasing tetracycline con-
centration. Furthermore, expression of tetA and tetR was
shown to be growth phase-dependent, and specifically in-
creased from lag to stationary phase in the presence of
tetracycline. However, such a growth-dependent increase
was not proportional for the two genes, resulting in a
gradual decrease of the tetA/tetR mRNA ratio from lag to
stationary phases. The basic observations behind the
tetR-tetA regulation model [24], the affinity studies and
promoter strength studies [42, 44] previously used to
explain regulation of TetA production at low concen-
trations of tetracycline also seem to be applicable to the
data obtained in the current study, which shows that
the tetracycline regulation model also applies at thera-
peutic tetracycline concentrations. Altogether these results
contribute to improve understanding of the relationships
between E. coli growth, exposure to tetracycline and ex-
pression of tetracycline resistance.
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growth rate. Length of lag phase and the specific maximum growth rate
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